CTOs on the Move

New York Cancer and Blood Specialists

www.nycancer.com

 
New York Cancer & Blood Specialists is committed to our patients. We are dedicated to providing each patient with a unique path to treatment and unmatched support. We strive to make quality, comprehensive cancer care available to each and every patient throughout New York.
  • Number of Employees: 1K-5K
  • Annual Revenue: $100-250 Million
  • www.nycancer.com
  • 1500 Route 112 Building 4
    Port Jefferson Station, NY USA 11776
  • Phone: 631.751.3000

Executives

Name Title Contact Details
Carlos Ng
Vice President of Information Technology Profile
Sean Riley
Chief Information Officer Profile

Similar Companies

Shire plc

Shire plc is a Radford, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Amneal

Amneal (NYSE:AMRX) is building one of the most dynamic pharmaceutical companies in our industry. Today`s healthcare environment requires new ideas. While staying true to our reputation for quality, service and value in pharmaceuticals, we are challenging ourselves, our playbook and the status quo. We are uniting people, passion and products to deliver outcomes that meet important medical needs, make quality medicines more accessible and more affordable, and provide solutions for tomorrow`s health challenges. We are Amneal and “We make healthy possible.” Learn more about how we`re making a difference in generics, brands and biosimilars at Amneal.com.

Predictive Oncology

Updates, earnings and commercializationListen to the audio recording of our recent shareholder call where we discussed the latest updates, gave an overview of our earnings report and highlighted the commercialization efforts underway at Predictive Onco...

Karyopharm

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm`s SINE compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm`s lead compound, XPOVIO™ (selinexor), received accelerated approval from the FDA in July 2019 in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. A Marketing Authorization Application for selinexor is also currently under review by the European Medicines Agency. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development.

Stayma Consulting Services

Stayma Consulting Services is a Alpharetta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.